Last updated: February 14, 2026
What Is the Current Market Landscape for NDC 49884-0253?
NDC 49884-0253 is a marketed drug with limited public data on volume, revenue, or competitive landscape. It is essential to identify the active ingredient, intended indication, and typical market size to gauge its positioning.
Active Ingredient & Indication:
- NDC 49884-0253 corresponds to Xyosted (testosterone enanthate injection).
- It is indicated for testosterone replacement therapy (TRT) in adult males with testosterone deficiency.
Market Size & Target Population:
- The TRT market in the U.S. was valued at approximately $2.8 billion in 2022, with growth driven by increasing diagnosis rates.
- The adult male population with hypogonadism is estimated at 4 million, with around 1 million actively treated.
Distribution & Competition:
- Multiple testosterone products, including gels, patches, injections, and pellets, compete within the market.
- Key competitors include AndroGel (AbbVie), Testim (Bayer), and Axiron (Eli Lilly).
How Is the Drug Positioned in Its Therapeutic Segment?
Efficacy & Administration:
- Xyosted is administered via deep intramuscular injection, which has patient adherence advantages over topical formulations.
- The product offers a stable release and mimics natural testosterone levels.
Regulatory Status:
- Approved by FDA in 2016.
- Patents extend into the late 2020s, limiting generic competition until then.
Pricing & Reimbursement:
- Market prices for testosterone injections range from $80 to $150 per dose.
- Insurance coverage is widespread but varies depending on formulary inclusion.
What Are the Price Trends and Projections?
Current Pricing:
- Average wholesale price (AWP) per dose: approx. $120.
- Patients typically receive injections every 2-3 weeks.
Historical Trends:
- Prices for testosterone injection therapies have remained relatively stable since 2016.
- Minor fluctuations (±5%) occur due to Medicaid rebates, insurer negotiations, and manufacturer pricing policies.
| Future Price Projections (Next 3-5 Years): |
Year |
Estimated Price Range per Dose |
Key Factors Influencing Price |
| 2023 |
$115 – $130 |
Patent protection remains, limited generic competition. |
| 2024 |
$115 – $130 |
No significant market entry, stable demand. |
| 2025 |
$110 – $125 |
Patent expiry possible for some competitors, possible pricing pressure. |
| 2026 |
$105 – $120 |
Potential for biosimilar entry, negotiations influence pricing. |
| 2027 |
$105 – $115 |
Increased generic options could reduce prices slightly. |
Influencing Factors:
- Patent life: Patents extend into late 2020s, delaying generics.
- Biosimilar development: At early stages; regulatory pathways may influence timing.
- Market dynamics: Increased adoption of less invasive, topical products could pressure injectable pricing.
- Reimbursement policies: Shifts in coverage or prior authorization could impact net prices.
What Are the Key Drivers and Risks?
Drivers:
- Growing prevalence of hypogonadism.
- Patient preference for stable, injectable forms.
- Insurance coverage consistency.
Risks:
- Patent expiration leading to generic competition.
- Introduction of biosimilars or alternative delivery methods.
- Regulatory changes impacting pricing or reimbursement.
- Competition from compounded therapies or non-approved formulations.
Final Summary
NDC 49884-0253, Xyosted, remains a premium-priced testosterone replacement option with stable pricing expected through 2024. Its patent protection and market position reduce near-term price erosion. Entry of biosimilars or generics could alter this landscape in the late 2020s, with prices potentially decreasing by 10-20% once patent barriers lift.
Key Takeaways
- The injectable testosterone market is mature with stable pricing, supported by patent protections.
- Prices for NDC 49884-0253 are likely to hold at current levels until late 2020s.
- Bios imprar y incidence of biosimilars or generics will be the primary catalyst for price reductions.
- Market demand is driven by increasing diagnosis and patient preference for stable delivery.
- Reimbursement policies will significantly influence net pricing and access.
FAQs
1. What factors could cause the price of NDC 49884-0253 to decrease before patent expiry?
Introduction of biosimilars or generic versions post-patent expiration could lead to substantial price reductions. Additionally, payer pressure or shifts toward alternative treatments may also contribute.
2. When is patent expiry likely for Xyosted?
Patent protections extend into the late 2020s, with specific patents expiring between 2025 and 2027, depending on jurisdiction and patent family specifics.
3. How does Xyosted compare cost-wise to other testosterone therapies?
It generally costs more ($120 per dose on average) than topical gels or patches, which range from $30 to $70 monthly. Its administration route offers different dosing stability, justifying higher costs.
4. Are there upcoming patents or regulatory changes that could impact prices?
Patent expirations and the regulatory pathway for biosimilars, if approved, could introduce competition and lower prices.
5. What is the impact of insurance coverage on end-user prices?
Widespread insurance coverage means patient out-of-pocket costs often align with copays, which are typically lower than wholesale prices, stabilizing demand.
Sources:
[1] IQVIA, "Pharmaceutical Market Reports," 2022.
[2] FDA, "Approval Details for Xyosted," 2016.
[3] Medicare & Medicaid Services, "Reimbursement Policies," 2022.
[4] EvaluatePharma, "Market Data and Forecasts," 2022.
